儿童期成人型非横纹肌肉瘤软组织肉瘤:复发后的挽救率与预后因素
该研究分析了1985至2020年间在一家儿童肉瘤转诊中心治疗的103例21岁以下复发成人型非横纹肌肉瘤软组织肉瘤(NRSTS)患者,首次复发中位时间为诊断后14个月,局部复发占47%、转移性占34%、两者兼有占19%。复发后中位总生存期(OS)为20个月,1年、5年、10年复发后OS分别为56.1%、25.8%、19.1%。多因素分析显示局部复发、晚期复发(首次诊断后超过12个月)及获得二次缓解与OS显著改善相关。
要点
- 复发后1年、5年、10年OS分别为56.1%、25.8%、19.1%,中位OS为20个月。
- 局部复发和晚期复发(>12个月)患者OS显著优于转移性或早期复发者。
- 获得二次缓解与OS显著改善相关,三者被组合用于风险适应模型。
核心结论
- 复发NRSTS患者结局较差,局部复发、晚期复发及获得二次缓解与OS显著改善相关。
- 上述变量被组合成风险适应模型,用于估算挽救机会并决定最佳二线治疗。
研究设计与样本
- 回顾性分析1985至2020年间在一家儿童肉瘤转诊中心治疗的103例21岁以下复发成人型NRSTS患者。
- 采用单因素和多因素分析,基于首次诊断临床特征、一线治疗、首次复发临床发现及二线治疗进行风险适应分层。
主要发现
- 首次复发发生于首次诊断后2至102个月(中位14个月),局部复发占47%、转移性占34%、两者兼有占19%。
- 复发时治疗包括化疗72例、放疗38例、手术55例。
- 复发后中位OS为20个月,1年、5年、10年复发后OS分别为56.1%、25.8%、19.1%。
- Cox多因素回归分析显示,局部复发和晚期复发(首次诊断后超过12个月)及获得二次缓解的患者OS显著更好。
关键数值与推荐
- 复发后1年OS为56.1%,5年OS为25.8%,10年OS为19.1%。
- 中位OS为20个月,首次复发中位时间为首次诊断后14个月(范围2至102个月)。
- 局部复发占47%,转移性复发占34%,局部合并转移占19%。
临床怎么用
- 作者将复发类型、复发时间及是否获得二次缓解组合成风险适应模型,用于估算挽救机会并决定最佳二线治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Though the prognosis for patients with pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) is generally good, the chances of being cured after relapse are limited. This report describes a series of relapsing NRSTS patients treated at a referral center for pediatric sarcoma, investigating the pattern of relapse, salvage rates, and factors correlating with the final outcome. METHODS: The analysis concerned 103 patients <21 years old with relapsing adult-type NRSTS treated from 1985 to 2020. For risk-adapted stratification purposes, the patient outcome was examined using univariable and multivariable analyses based on patients' clinical features at first diagnosis, first-line treatments, clinical findings at first relapse, and second-line treatments. RESULTS: The first relapse occurred within 2-102 months (median 14 months) after patients' first diagnosis and was local in 47%, metastatic in 34%, and both in 19%. Treatment at relapse included chemotherapy in 72 patients, radiotherapy in 38, and surgery in 55. The median overall survival (OS) was 20 months. Post-relapse OS was 56.1%, 25.8%, and 19.1% at 1, 5, and 10 years, respectively. Cox's multivariable regression analysis showed that OS was significantly better for patients with local and late relapses (occurring more than 12 months after their first diagnosis) and for those achieving secondary remission. CONCLUSION: The outcome of patients with recurrent NRSTS is poor. The above-mentioned variables (type and time of relapse and achievement of secondary remission) were combined in a risk-adapted model to develop a tool for estimating the chance of salvage and deciding the best second-line treatment approach.
引用
- Chiaravalli S, Bergamaschi L, Livellara V, et al. Adult-type non-rhabdomyosarcoma soft tissue sarcomas in pediatric age: Salvage rates and prognostic factors after relapse. Eur J Cancer. 2022. PMID: 35576803. doi:10.1016/j.ejca.2022.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。